These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 17596374)

  • 1. Exacerbation of dopaminergic terminal damage in a mouse model of Parkinson's disease by the G-protein-coupled receptor protease-activated receptor 1.
    Hamill CE; Caudle WM; Richardson JR; Yuan H; Pennell KD; Greene JG; Miller GW; Traynelis SF
    Mol Pharmacol; 2007 Sep; 72(3):653-64. PubMed ID: 17596374
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson's disease.
    Breidert T; Callebert J; Heneka MT; Landreth G; Launay JM; Hirsch EC
    J Neurochem; 2002 Aug; 82(3):615-24. PubMed ID: 12153485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulation of dopaminergic loss by Fas in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease.
    Hayley S; Crocker SJ; Smith PD; Shree T; Jackson-Lewis V; Przedborski S; Mount M; Slack R; Anisman H; Park DS
    J Neurosci; 2004 Feb; 24(8):2045-53. PubMed ID: 14985447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.
    Novikova L; Garris BL; Garris DR; Lau YS
    Neuroscience; 2006 Jun; 140(1):67-76. PubMed ID: 16533572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Riluzole (2-amino-6-trifluoromethoxy benzothiazole) attenuates MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) neurotoxicity in mice.
    Araki T; Muramatsu Y; Tanaka K; Matsubara M; Imai Y
    Neurosci Lett; 2001 Oct; 312(1):50-4. PubMed ID: 11578843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of S-100 protein is related to neuronal damage in MPTP-treated mice.
    Muramatsu Y; Kurosaki R; Watanabe H; Michimata M; Matsubara M; Imai Y; Araki T
    Glia; 2003 May; 42(3):307-13. PubMed ID: 12673835
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased vulnerability of dopaminergic neurons in MPTP-lesioned interleukin-6 deficient mice.
    Bolin LM; Strycharska-Orczyk I; Murray R; Langston JW; Di Monte D
    J Neurochem; 2002 Oct; 83(1):167-75. PubMed ID: 12358740
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential neuroprotective effect of low dose whole-body gamma-irradiation against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic toxicity in C57 mice.
    Liang Y; Li S; Zou Q; Su B
    Neurosci Lett; 2006 Jun; 400(3):213-7. PubMed ID: 16540245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alpha-synuclein up-regulation in substantia nigra dopaminergic neurons following administration of the parkinsonian toxin MPTP.
    Vila M; Vukosavic S; Jackson-Lewis V; Neystat M; Jakowec M; Przedborski S
    J Neurochem; 2000 Feb; 74(2):721-9. PubMed ID: 10646524
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mouse model of Parkinsonism: a comparison between subacute MPTP and chronic MPTP/probenecid treatment.
    Petroske E; Meredith GE; Callen S; Totterdell S; Lau YS
    Neuroscience; 2001; 106(3):589-601. PubMed ID: 11591459
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MTH1, an oxidized purine nucleoside triphosphatase, protects the dopamine neurons from oxidative damage in nucleic acids caused by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
    Yamaguchi H; Kajitani K; Dan Y; Furuichi M; Ohno M; Sakumi K; Kang D; Nakabeppu Y
    Cell Death Differ; 2006 Apr; 13(4):551-63. PubMed ID: 16273081
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intervention with exercise restores motor deficits but not nigrostriatal loss in a progressive MPTP mouse model of Parkinson's disease.
    Sconce MD; Churchill MJ; Greene RE; Meshul CK
    Neuroscience; 2015 Jul; 299():156-74. PubMed ID: 25943481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuroprotective effects of genistein on dopaminergic neurons in the mice model of Parkinson's disease.
    Liu LX; Chen WF; Xie JX; Wong MS
    Neurosci Res; 2008 Feb; 60(2):156-61. PubMed ID: 18054104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activated microglia affect the nigro-striatal dopamine neurons differently in neonatal and aged mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
    Sawada H; Hishida R; Hirata Y; Ono K; Suzuki H; Muramatsu S; Nakano I; Nagatsu T; Sawada M
    J Neurosci Res; 2007 Jun; 85(8):1752-61. PubMed ID: 17469135
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single low doses of MPTP decrease tyrosine hydroxylase expression in the absence of overt neuron loss.
    Alam G; Edler M; Burchfield S; Richardson JR
    Neurotoxicology; 2017 May; 60():99-106. PubMed ID: 28377118
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CX3CR1 Disruption Differentially Influences Dopaminergic Neuron Degeneration in Parkinsonian Mice Depending on the Neurotoxin and Route of Administration.
    Tristão FS; Lazzarini M; Martin S; Amar M; Stühmer W; Kirchhoff F; Gomes LA; Lanfumey L; Prediger RD; Sepulveda JE; Del-Bel EA; Raisman-Vozari R
    Neurotox Res; 2016 Apr; 29(3):364-80. PubMed ID: 26403659
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of peroxisome proliferator-activated receptor-gamma in the substantia nigra of hemiparkinsonian nonhuman primates.
    Swanson C; Emborg M
    Neurol Res; 2014 Jul; 36(7):634-46. PubMed ID: 24620964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Damage to the nigrostriatal system in the MPTP-treated SAMP8 mouse.
    Liu J; Wang YY; Liu L; Wang QD; Yuan ZY; Zhang ZX; Gu P; Wang MW
    Neurosci Lett; 2008 Dec; 448(2):184-8. PubMed ID: 18977411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Granulocyte-colony stimulating factor is neuroprotective in a model of Parkinson's disease.
    Meuer K; Pitzer C; Teismann P; Krüger C; Göricke B; Laage R; Lingor P; Peters K; Schlachetzki JC; Kobayashi K; Dietz GP; Weber D; Ferger B; Schäbitz WR; Bach A; Schulz JB; Bähr M; Schneider A; Weishaupt JH
    J Neurochem; 2006 May; 97(3):675-86. PubMed ID: 16573658
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuroprotective effects of (+/-)-kavain in the MPTP mouse model of Parkinson's disease.
    Schmidt N; Ferger B
    Synapse; 2001 Apr; 40(1):47-54. PubMed ID: 11170221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.